All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

FDA-&-EMA-New-Drug Approvals(Mid-2020 Recap)-insert

X

Find Clinical Drug Pipeline Developments & Deals by BioIntervene

All Data

Filters

refresh

×

FILTER DATA :

Therapeutic Area

Study Phase

Country

News Type

Company

refresh

Companies By Therapeutic Area

Development Status

BioIntervene

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Chinaplas 2020

Participation Not Confirmed

Update your events

MPM backs new biotech in the hunt for non-opioid painkiller

Contact the Supplier

Lead Product(s): BIO-205

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: MPM Capital

Deal Size: $30.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing January 07, 2020

Details:

The financing will be used to advance the company’s lead program, BIO-205, through human proof-of-concept studies in neuropathic pain as well as to advance its portfolio of A3AR agonists.